EMA Revises Guidance for Its “PRIME Scheme” Drug Development Assistance Program

By PacConAdmin | July 11, 2023

EMA has issued revised guidance for its PRIority MEdicines (PRIME) scheme that provides early consultation and scientific advice between applicants and regulators for medicines under development and not currently authorized in the EU.
Source: Drug Industry Daily

Posted in Drug Industry Daily